MyFinsight
Home
Blog
About
Comprehensive loss
-$314,811
(-26.38%↓ Y/Y)
Net loss
attributable to common...
-$286,451
(53.51%↑ Y/Y)
Foreign currency
translation (loss)/gain
-$28,360
Loss before tax
-$286,451
(53.51%↑ Y/Y)
Reversal of expected
credit losses
$91,383
(31.00%↑ Y/Y)
Interest income
$21,183
(-28.84%↓ Y/Y)
Others
$8,393
(-89.18%↓ Y/Y)
Gain from foreign
exchange
$46
Revenue (including nil
and 16,109 of...
$76,156
(-96.63%↓ Y/Y)
Loss from operations
-$282,396
(53.80%↑ Y/Y)
Finance costs
$4,055
(-16.89%↓ Y/Y)
Total other income
$121,005
(-42.23%↓ Y/Y)
Gross profit
$12,982
(-96.47%↓ Y/Y)
Cost of revenue
(including nil and 2,307 of...
$63,174
(-96.66%↓ Y/Y)
Total operating
expenses
$416,383
(-64.97%↓ Y/Y)
General and
administrative (including nil...
$298,526
(-42.23%↓ Y/Y)
Provision for expected
credit gaines
$68,164
Sales and marketing
$36,022
(-94.08%↓ Y/Y)
Research and development
$13,671
(8.87%↑ Y/Y)
Back
Back
Income Statement
BioNexus Gene Lab Corp (BGLC)
BioNexus Gene Lab Corp (BGLC)
source: myfinsight.com